Global Alzheimer’s Disease Therapeutics Market 2020-2024 | Evolving Opportunities with Allergan Plc and Eisai Co. Ltd. | Technavio

LONDON–(BUSINESS WIRE)–#Biotechnology–Technavio has been monitoring the global Alzheimer’s disease therapeutics market and the market is poised to grow by USD 3.17 billion during 2020-2024 at a CAGR of almost 9% during the forecast period. Request Free Sample Pages

Read the 158-page research report with TOC on “Alzheimer’s Disease Therapeutics Market Analysis Report by Geography (Asia, Europe, North America, and ROW), by Drug class (Cholinesterase inhibitors, N-methyl-D-aspartate receptor antagonist, and Other drug class), and Segment Forecasts, 2020-2024″.

https://www.technavio.com/report/alzheimer-s-disease-therapeutics-market-industry-analysis

The availability, research, and development of novel biomarkers and emergence of regenerative therapies is anticipated to boost the growth of the market.

The development of new therapies to treat patients with Alzheimer’s disease involves the identification of disease-modifying therapies and clinical trials. This is driving the need for biomarkers in the development process as they allow tests of bodily fluids and cerebral spinal fluids. They also allow tests of neuroimaging scans such as magnetic resonance imaging (MRI) and positron emission tomography (PET). There are several biomarkers currently in use, including cerebrospinal fluid biomarkers, biomarkers for tau pathology, biomarkers for PET, biomarkers for β-amyloid pathology. Thus, the availability, research, and development of novel biomarkers is expected to drive market growth during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Alzheimer’s Disease Therapeutics Market Companies:

Allergan Plc

Allergan Plc is headquartered in Ireland and operates the business under various segments such as US specialized therapeutics, US general medicine, and International. The company offers NAMENDA XR/NAMENDA, which is used to treat moderate to severe Alzheimer’s disease.

Aurobindo Pharma Ltd.

Aurobindo Pharma Ltd. is headquartered in India and offers products through the business unit: Pharmaceuticals. The company offers Donepezil, which is used to treat symptoms of Alzheimer’s disease.

Eisai Co. Ltd.

Eisai Co. Ltd. is headquartered in Japan and operates under various business segments, namely Pharmaceutical business and Other business. The company offers Aricept, which is used to treat the symptoms of dementia caused by Alzheimer’s disease.

Eli Lilly and Co.

Eli Lilly and Co. is headquartered in the US and offers products through the following business segments: Human pharmaceutical products and Animal health products. The company offers LY2062430 (solanezumab), which is being studied for its potential to slow the progression of Alzheimer’s disease and is in Phase III of clinical trials.

H. Lundbeck AS

H. Lundbeck AS is headquartered in Denmark and offers products through the business segment: Pharmaceuticals. The company offers Brexpiprazole, for the potential treatment of agitation and, Ebixa for the treatment of moderate to severe Alzheimer’s disease.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio’s SUBSCRIPTION platform

Alzheimer’s Disease Therapeutics Drug Class Outlook (Revenue, USD Million, 2020-2024)

• Cholinesterase inhibitors
• N-methyl-d-aspartate receptor antagonist
• Other drug class

Alzheimer’s Disease Therapeutics Regional Outlook (Revenue, USD Million, 2020-2024)

• Asia
• Europe
• North America
• ROW

Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: [email protected]
Website: https://www.technavio.com